Scholarlink

Background <p>Chyle leak is a relevant complication after surgery for pancreatic ductal adenocarcinoma (PDAC). Increasing use of multimodal neoadjuvant therapy (NAT) and extended resections may contribute to a higher incidence. This study aimed to describe the incidence of clinically relevant chyle leak and identify its risk factors in patients with PDAC treated with NAT and surgery versus upfront surgery.</p> Patients and Methods <p>Patients undergoing PDAC resection between 2014 and 2019 were identified from a prospective institutional database. Clinicopathologic and demographic data were extracted. The primary outcome was clinically relevant chyle leak according to the International Study Group of Pancreatic Surgery (ISGPS). Univariable and multivariable logistic regression were performed to identify associated factors.</p> Results <p>A total of 1402 patients were included: 1090 (77.7%) underwent upfront surgery, and 312 (22.3%) received NAT. Pancreatic head resections were performed in 718 (51.2%), distal pancreatectomies in 317 (22.6%), and total pancreatectomies in 367 (26.2%) individuals. Overall, 108 (7.7%) developed clinically relevant chyle leak: 88 (6.3%) grade B and 20 (1.4%) grade C. NAT (odds ratio [OR] 1.45, 95% confidence interval [CI] 1.10–1.91), T stage (pT2/3/4 versus pT0/1, OR 1.53, 95% CI 1.03–2.34), and total pancreatectomy (OR 2.29, 95% CI 1.78–2.96) were associated with any chyle leak. For grade B/C, only NAT was an independent risk factor (OR 2.63, 95% CI 1.74–3.94). Age, resection type, and nodal status were not independent risk factors.</p> Conclusions <p>NAT is an independent risk factor for clinically relevant chyle leak following PDAC resection. These findings highlight the need for risk-adapted postoperative management and warrant prospective validation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Neoadjuvant Treatment is a Risk Factor for Clinically Relevant Chyle Leak (ISGPS Grade B/C) After Pancreatic Cancer Resection: A Retrospective Cohort Study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月21日

查看全文
  • Carl-Stephan Leonhardt,
  • Sakher Shraim,
  • Karim Abdelazim,
  • Ulf Hinz,
  • Georgios Polychronidis,
  • Thomas Hank,
  • Martin Schneider,
  • Thilo Hackert,
  • Oliver Strobel,
  • Martin Loos,
  • Markus W. Buechler,
  • Mohammed Al-Saeedi

摘要

Background

Chyle leak is a relevant complication after surgery for pancreatic ductal adenocarcinoma (PDAC). Increasing use of multimodal neoadjuvant therapy (NAT) and extended resections may contribute to a higher incidence. This study aimed to describe the incidence of clinically relevant chyle leak and identify its risk factors in patients with PDAC treated with NAT and surgery versus upfront surgery.

Patients and Methods

Patients undergoing PDAC resection between 2014 and 2019 were identified from a prospective institutional database. Clinicopathologic and demographic data were extracted. The primary outcome was clinically relevant chyle leak according to the International Study Group of Pancreatic Surgery (ISGPS). Univariable and multivariable logistic regression were performed to identify associated factors.

Results

A total of 1402 patients were included: 1090 (77.7%) underwent upfront surgery, and 312 (22.3%) received NAT. Pancreatic head resections were performed in 718 (51.2%), distal pancreatectomies in 317 (22.6%), and total pancreatectomies in 367 (26.2%) individuals. Overall, 108 (7.7%) developed clinically relevant chyle leak: 88 (6.3%) grade B and 20 (1.4%) grade C. NAT (odds ratio [OR] 1.45, 95% confidence interval [CI] 1.10–1.91), T stage (pT2/3/4 versus pT0/1, OR 1.53, 95% CI 1.03–2.34), and total pancreatectomy (OR 2.29, 95% CI 1.78–2.96) were associated with any chyle leak. For grade B/C, only NAT was an independent risk factor (OR 2.63, 95% CI 1.74–3.94). Age, resection type, and nodal status were not independent risk factors.

Conclusions

NAT is an independent risk factor for clinically relevant chyle leak following PDAC resection. These findings highlight the need for risk-adapted postoperative management and warrant prospective validation.